Research Advances on Combination Strategies of Demethylating Agents for Elderly Acute Myeloid Leukemia--Review.
10.19746/j.cnki.issn.1009-2137.2019.04.058
- Author:
Wen-Xuan SUN
1
;
Bin JIANG
2
Author Information
1. Department of Hematology，Peking University International Hospital，Beijing 102206，China.
2. Department of Hematology，Peking University International Hospital，Beijing 102206，China,E-mail：jiangbin@pkuih.edu.cn.
- Publication Type:Journal Article
- MeSH:
Aclarubicin;
Aged;
Antineoplastic Combined Chemotherapy Protocols;
Cytarabine;
Granulocyte Colony-Stimulating Factor;
Humans;
Isocitrate Dehydrogenase;
Leukemia, Myeloid, Acute
- From:
Journal of Experimental Hematology
2019;27(4):1339-1343
- CountryChina
- Language:Chinese
-
Abstract:
Abstract Demethylating agents (HMAs) hold an important status in therapy for elderly acute myeloid leukemia, who are not eligible for intensive chemotherapy (ICT). Beyond the edge of monotherapy, domestic and foreign scholars have carried out a lot of studies on combination strategies, such as HMAs with low-intensity therapy (G-CSF, low-dose cytarabine and aclarubicin, CAG), with targeted therapy (BCL-2 inhibitor), with immunotherapy (immune checkpoint inhibitors, ICI), and with other epigenetic therapys (isocitrate dehydrogenase or histonedeacetylase inhibitor）. Some of these researches have obtained positive results and discussed the mechanisms of combination strategies besides. In this review, the combination of HMAs with other drugs are summraized briefly.
